Novartis' Afinitor nabs FDA nod to treat kids' brain tumors; Abbott gets new Humira use in EU;

 @FiercePharma: Two drugmakers hit the Forbes "Fab 50" in Asia: Australia's CSL and India's Sun Pharma. Item | Follow @FiercePharma

> Novartis ($NVS) won FDA approval for a new formulation of its Afinitor cancer treatment, Afinitor Disperz, for children with a rare type of brain tumor. Report

> On the heels of an FDA panel recommendation in the U.S., Abbott Laboratories' ($ABT) Humira nabbed a new use in Europe in patients with moderately active Crohn's disease. Report

> GlaxoSmithKline ($GSK) said it would continue to negotiate with local officials in Montrose, Scotland, after officials rejected its wind-turbine plan designed to power a local plant that's slated for expansion. Report

> Brazil's Hypermarcas is reaping the rewards of a restructuring that refocused its operations on drugs and beauty products. Report

> Quality Packaging Specialists, a New Jersey pharma packaging firm, will move a plant to Pennsylvania and create 283 jobs there over the next three years, officials said. Report

> Switzerland's Siegfried said its active pharmaceuticals ingredient business grew by 2.9% for the first 6 months of 2012, to $185 million, as it prepares to expand operations in China. Report

> China's Fosun Pharma nabbed $47 million in financing from the World Bank's International Finance Corporation, to upgrade manufacturing facilities, including those in less-developed regions. Report

Medical Device News

 @FierceMedDev: Bacterin International, a maker of bone graft material and antimicrobial coatings, won $25M in financing from OrbiMed. Release | Follow @FierceMedDev

 @MarkHFierce: BSX is slashing more jobs and splitting its cardio business in two--undoing changes enacted by the old CEO. More | Follow @MarkHFierce

 @DamianFierce: Baxter is recalling four Automix devices over a deadly malfunction risk. The FDA has labeled it a Class I. News | Follow @DamianFierce

> Zynex gets 510(k) for urinary incontinence device. News

> MDxHealth's revenues soar, losses deepen in H1. Item

Biotech News

 @FierceBiotech: XBiotech hatches big plans for Austin campus. Item | Follow @FierceBiotech

 @JohnCFierce: At long last, Ironwood gets its OK, shifts to commercialization alongside development. News | Follow @JohnCFierce

 @RyanMFierce: After reading through this OvaScience S-1, looks like VCs are in fact cashing out, some want to unload most of their shares. | Follow @RyanMFierce

> Cincy biotech spinoff snags $27M A round for vascular drug work. Story

> Novartis ready to present blockbuster COPD hopeful QVA149 to regulators. Article

> Teva's Neupogen-knockoff approval highlights slow progress of biosims. More

> J&J grabs Genmab's promising leukemia antibody in $1.1B deal. News

Pharma Manufacturing News

 @EricPFierce: Hospira goes back to Orchid, picks up API plant, R&D center for $200 million. Good news tainted a bit by FDA warning. Story | Follow @EricPFierce

> Closed plants lead Novartis to plead for vet loyalty. Story

> Claris squares off against former partners in U.S. injectables market. Article

> Scots reject GSK wind turbines; tidal turbines up next. Story

Vaccines News

 @AlisonBFierce: What does AstraZeneca's new CEO mean to vaccinemaker MedImmune? More | Follow @AlisonBFierce

> S. Korea, Sweden partner up to find Alzheimer's vaccine. Item

> West Nile virus breaks out in the South. News

> CSL nets closeout letter after FDA violations. More

> Flu adjuvant adds promise to vaccine. Report

And Finally ... Tuberculosis cases around the world are growing increasingly resistant to virtually all treatments, a study found. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.